Nebula Research & Development LLC Takes Position in Tempus AI, Inc. (NASDAQ:TEM)

Nebula Research & Development LLC purchased a new position in shares of Tempus AI, Inc. (NASDAQ:TEM) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 13,349 shares of the company’s stock, valued at approximately $451,000.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Operose Advisors LLC acquired a new position in shares of Tempus AI during the fourth quarter worth approximately $25,000. Farther Finance Advisors LLC bought a new position in Tempus AI in the 4th quarter valued at $34,000. Prestige Wealth Management Group LLC increased its stake in shares of Tempus AI by 910.4% in the 4th quarter. Prestige Wealth Management Group LLC now owns 1,071 shares of the company’s stock valued at $36,000 after buying an additional 965 shares during the period. NewEdge Advisors LLC bought a new stake in shares of Tempus AI during the fourth quarter worth $49,000. Finally, First Horizon Advisors Inc. lifted its stake in shares of Tempus AI by 207.9% during the fourth quarter. First Horizon Advisors Inc. now owns 1,641 shares of the company’s stock valued at $55,000 after acquiring an additional 1,108 shares during the period. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Trading Up 1.0 %

Shares of TEM opened at $54.29 on Wednesday. Tempus AI, Inc. has a twelve month low of $22.89 and a twelve month high of $91.45. The company has a quick ratio of 2.55, a current ratio of 2.69 and a debt-to-equity ratio of 8.17. The firm’s 50 day moving average price is $48.83 and its two-hundred day moving average price is $50.54.

Wall Street Analyst Weigh In

Several analysts have weighed in on the company. Wolfe Research cut Tempus AI from a “strong-buy” rating to a “hold” rating in a report on Wednesday, February 26th. Loop Capital cut their price objective on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating on the stock in a report on Tuesday, January 14th. JPMorgan Chase & Co. lowered shares of Tempus AI from an “overweight” rating to a “neutral” rating and lifted their target price for the stock from $50.00 to $55.00 in a report on Tuesday, February 25th. Piper Sandler cut their price target on Tempus AI from $70.00 to $55.00 and set a “neutral” rating on the stock in a research note on Tuesday, March 4th. Finally, Needham & Company LLC reiterated a “buy” rating and issued a $70.00 price objective on shares of Tempus AI in a report on Thursday, April 24th. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $61.08.

Insider Activity at Tempus AI

In other Tempus AI news, CEO Eric P. Lefkofsky sold 3,240,234 shares of the company’s stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $58.75, for a total transaction of $190,363,747.50. Following the completion of the transaction, the chief executive officer now owns 4,895,589 shares of the company’s stock, valued at $287,615,853.75. This represents a 39.83 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Wayne A.I. Frederick sold 3,000 shares of the business’s stock in a transaction on Monday, March 31st. The stock was sold at an average price of $45.54, for a total transaction of $136,620.00. Following the completion of the sale, the director now directly owns 26,514 shares in the company, valued at approximately $1,207,447.56. This represents a 10.16 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 4,505,134 shares of company stock valued at $268,609,285. 27.60% of the stock is owned by corporate insiders.

Tempus AI Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.